Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Peter A, MD
19 Machi 2021 19:25:18
Zidovudine na ujauzito
Zidovudine (AZT) ni dawa nzuri yenye uwezo wa kupunguza maambukizi ya UKIMWI (HIV-1) kutoka kwa mama kwenda kwa mtoto . Hata hivyo dawa hii husababisha upungufu wa damu kwa vichanga na endapo itatumika huhitaji kuwa chini ya uangalizi. Hata kama bado haijathibitishwa, inafahamika kuwa AZT hupunguza maambukizi kupitia mbegu za kiume kutoka kwa baba kwenda kwa mama wakati wote wa ujauzito. Dawa hii pia haipo kwenye kundi la dawa zinazosababisha madhaifu kwa kichanga cha wanyama wajawazito isipokuwa endapo itatumiwa kwa dozi kubwa. Uzoefu wa matumizi kwa binadamu unaonyesha kuwa dawa hii haihusiani na madhaifu ya kiuumbaji kwa kichanga wa binadamu wajawazito. Kuna baadhi ya majaribio ya tafiti za kisayansi zimeonyesha dawa hii kuhusiana na kuingilia kiini. Kutokana na kukosekana kwa ushahidi wa kutosha kwa biandamu, endapo dawa hii ni muhimu kutumika, pasipo kuhofia madhara katika ujauzito.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni, ina maana gani?
Kunaweza kuwa au kutokuwa na uzoefu wa matumizi ya dawa hii kwa binadamu, lakini faida ni kubwa zaidi zikitumiwa na mama kuliko madhara yanayofahamika au kutofahamika kuwa yanaweza kutokea kwa kijusi-kichanganya tumboni. Kwa mama dawa zinazidi madhara yanayofahammika. Taarifa za uzazi kwa wanyama hazina mahusiano
Ushauri wa matumizi kwa mama anayenyonyesha
Haipatani na unyoyenyeshaji
Haipatani na unyoyenyeshaji, ina maana gani?
Kunawezekana kuwa hakuna taarifa za uzoefu wa matumizi ya dawa hii kwa mama anayenyonyesha. Hata hivyo mkusanyiko wa taarifa zinaonyesha kuwa dawa huweza kuwa sumu kali kwa kichanga, au haishauriwi kunyonyesha endapo dawa itahitajika kutumika kwa mama mwenye anayehitajika kutumia dawa hii. Mama anatakiwa asinyonyeshe anapotumia dawa hii au akiwa na ugonjwa unaotakiwa kutumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. Product information. Retrovir. Glaxo Wellcome, 2001.
2. Klug S, et al. In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir. Arch Toxicol 1991;65:283–91.
3. Greene JA, et al. Postnatal survival in Wistar rats following oraldosage with zidovudine on gestation day 10. Fund Appl Toxicol 1990;15:201–6.
4. Gogu SR, et al. Amelioration of zidovudine-induced fetal toxicity in pregnant mice. Antimicrob Agents Chemother 1992;36:2370–4.
5. Toltzis P, et al. Zidovudine-associated embryonic toxicity in mice. J Infect Dis 1991;1212–8.
6. Sieh E et al.The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses 1992;8:639–49.
7. Toltzis P, et al. Effect of zidovudine on preimplantation murine embryos. Antimicrob Agents Chemother 1993;37:1610–3.
8. Toltzis P, et al. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100–2.
9. Nosbisch C, et al. Fetal and infant toxicity of zidovudine in Macaca nemestrina (abstract). Teratology 1994;49:415.
10. Ha JC, et al. Fetal toxicity of zidovudine (azidothymidine) in Macaca nemestrina: preliminary observations. J Acquir Immune Defic
1. Synd 1994;7:154–7.
11. Esterman AL, et al. The effect of zidovudine and 2’3’-dideoxyinosine on human trophoblast in culture. Pharmacol Toxicol 1995;76:89–92.
12. Plessinger MA, Miller RK. Effects of zidovudine (AZT) and dideoxyinosine (ddI) on human trophoblast cells. Reprod Toxicol 1999;13:537–46.
13. Venerosi A, et al. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001;63:26–37.
14. Unadkat JD, Lopez AA, Schuman L. Transplacental transfer and the pharmacokinetics of zidovudine (ZDV) in the near term pregnant macaque. In: Program and Abstracts of the Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, October 1988 . Los Angeles, CA:
15. American Society for Microbiology, 1988:372. As cited in Hankins GDV, Lowery CL, Scott RT, Morrow WR, Carey KD, Leland MM, Colvin EV. Transplacental transfer of zidovudine in the near-term pregnant baboon. Am J Obstet Gynecol 1990;163:728–32. 15. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL. Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer. J Acquir Immune Defic Synd 1990;3:959–64.
16. Hankins GDV et al. Transplacental transfer of zidovudine in the near-term pregnant baboon. Am J Obstet Gynecol 1990;163:728–32.
17. Liebes L, et al. Transfer of zidovudine (AZT) by human placenta. J Infect Dis 1990;161:203–7.
18. Bawdon RE, et al. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol 1992;167:1570–4.
19. Schenker S, et al. Azidothymidine (zidovudine) transport 2 by the human placenta. Am J Med Sci 1990;299:16–20.
20. Gillet JY, et al. Fetoplacental passage of zidovudine. Lancet 1989;2:269–70.
21. Lyman WD, et al. Zidovudine concentrationsin human fetal tissue: implications for perinatal AIDS. Lancet 1990;335:1280–1.
22. Chavanet P, et al. Perinatal pharmacokinetics of zidovudine. N Engl J Med 1989;321:1548–9.
23. Pons JC, et al. Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Eur J Obstet Gynecol Reprod Biol 1991;40:229–31.
24. O’Sullivan MJ, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials group study (protocol 082). Am J Obstet Gynecol 1993;168:1510–6.
25. Unadkat JD, Pereira CM. Maternal-fetal transfer and fetal toxicity of anti-HIV drugs. A review. Trophoblast Res 1994;8:67–82.
26. Watts DH, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991;163:226–32.
27. Sperling RS, et al. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992;9:247–9.
28. Ruff A, Hamzeh, Lietman P, Siberry G, Boulos R, Bell K, McBrien M, Davis H, Coberly J, Joseph D, Halsey N. Excretion of Zidovudine (ZDV) in Human Breast Milk (Abstract). Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, FL, October, 1994.
29. Brown ZA, Watts DH. Antiviral therapy in pregnancy. Clin Obstet Gynecol 1990;33:276–89.
30. De Martino M, et al. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS 1992;6:991–7.
31. Van de Perre P. Postnatal transmission of human immunodeficiency virus type 1: the breast-feeding dilemma. Am J Obstet Gynecol 1995;173:483–7.